



Regular Meeting of the
Santa Clara County Health Authority
Pharmacy and Therapeutics (P&T) Committee

Thursday, September 16, 2021, 6:00 - 8:00 PM
 Santa Clara Family Health Plan
 6201 San Ignacio Ave, San Jose, CA 95119

Via Teleconference
 (408) 638-0968
 Meeting ID: 845 3667 0431
 Passcode: **SCFHP123**
<https://us06web.zoom.us/j/84536670431>

AGENDA

1. Roll Call / Establish Quorum	Dr. Lin	6:00	5 min
2. Public Comment Members of the public may speak to any item not on the agenda; two minutes per speaker. The Committee reserves the right to limit the duration of the public comment period to 30 minutes.	Dr. Lin	6:05	5 min
3. Open Meeting Minutes Review Santa Clara Family Health Plan (SCFHP) 2Q 2021 P&T Open Session Minutes. Possible Action: Approve SCFHP P&T Open Session Minutes	Dr. Lin	6:10	2 min
4. Standing Agenda Items			
a. Chief Medical Officer Health Plan Updates	Dr. Nakahira	6:12	5 min
b. Medi-Cal Rx Update	Dr. Otomo	6:17	3 min
c. Plan/Global Medi-Cal Drug Use Review	Dr. Otomo	6:20	4 min
i. Drug Utilization Evaluation Update			
<i>Adjourn to Closed Session</i>			
<i>Pursuant to Welfare and Institutions Code Section 14087.36 (w)</i>			
5. Closed Meeting Minutes Review SCFHP 2Q 2021 P&T Closed Session Minutes. Possible Action: Approve SCFHP P&T Closed Session Minutes	Dr. Lin	6:24	2 min
6. Metrics & Financial Updates			
a. Membership Report	Dr. Nakahira	6:26	3 min
b. Pharmacy Dashboard	Dr. Otomo	6:29	5 min
c. Pharmacy Member Portal Stats – 1H 2021	Dr. Otomo	6:34	2 min
d. Drug Utilization & Spend – 2Q 2021	Dr. McCarty	6:36	5 min

<p>7. Discussion and Recommendations for Changes to SCFHP's Cal MediConnect Formulary & Coverage Determination Criteria</p> <p>a. Pharmacy Benefit Manager 2Q 2021 P&T Minutes</p> <p>b. Pharmacy Benefit Manager 3Q 2021 P&T Part D Actions</p> <p>Possible Action: Approve MedImpact Minutes & Actions</p>	Dr. McCarty	6:41	3 min
<p>8. Discussion and Recommendations for Changes to SCFHP's Medi-Cal Formulary & Prior Authorization Criteria</p> <p>a. Old Business/Follow-Up – SGLT2i and SGLT2i combination products</p> <p>b. Formulary Modifications</p> <p>Possible Action: Approve Formulary Addition and Modification Recommendations</p>	Dr. Otomo	6:44	3 min
<p>c. Fee-for-Service Contract Drug List Comparability</p> <p>Possible Action: Approve CDL Comparability Formulary Recommendations</p>	Dr. McCarty	6:50	5 min
<p>d. Prior Authorization Criteria</p> <p>i. <u>New/Revised Criteria</u></p> <p>1. Vfend</p> <p>ii. <u>Annual Review</u></p> <p>1. Compounded Medications</p> <p>2. Duragesic</p> <p>3. Emend</p> <p>4. Enablex</p> <p>5. Enbrel</p> <p>6. Insulin Pens</p> <p>7. Myrbetriq</p> <p>8. Nicotrol</p> <p>9. Off-label</p> <p>10. Opioid Safety Edits</p> <p>11. Penlac</p> <p>12. Quantity Limit</p> <p>13. Retacrit</p> <p>14. Taltz</p> <p>15. Trintellix</p> <p>16. Xelpros</p> <p>17. Zyvox</p> <p>Possible Action: Approve PA Criteria Recommendations</p>	Dr. Nguyen	6:55	10 min
<p>9. New Drugs and Class Review</p> <p>a. Pneumococcal vaccines</p> <p>b. Heart Failure Update - Jardiance & Entresto</p> <p>c. Granulocyte Colony-Stimulating Factors (GCSF)</p> <p>d. Xyrem & Xywav</p> <p>e. Dupixent</p> <p>f. New Entities & Combinations – Brexafemme, Accrufer, Azstarys</p> <p>g. New Indications – Zeposia</p> <p>h. COVID-19 Treatment - sotrovimab</p> <p>Possible Action: Approve New Drug and Class Recommendations</p>	Dr. McCarty	7:05	50 min

Reconvene in Open Session

10. Discussion Items

a. New and Generic Pipeline

Dr. McCarty 7:55 5 min

11. Adjournment

Next meeting Thursday December 16, 2021

Dr. Lin 8:00

Notice to the Public—Meeting Procedures

- Persons wishing to address the Committee on any item on the agenda are requested to advise the Recorder so that the Chairperson can call on them when the item comes up for discussion.
- The Committee may take other actions relating to the issues as may be determined following consideration of the matter and discussion of the possible action.
- In compliance with the Americans with Disabilities Act, those requiring accommodations in this meeting should notify Nancy Aguirre 48 hours prior to the meeting at 408-874-1835.
- To obtain a copy of any supporting document that is available, contact Nancy Aguirre at 408-874-1835. Agenda materials distributed less than 72 hours before a meeting can be inspected at the Santa Clara Family Health Plan offices at 6201 San Ignacio Ave, San Jose, CA 95119.

This agenda and meeting documents are available at www.scfhp.com

Pharmacy & Therapeutics Committee

OPEN MEETING MINUTES

Regular Meeting of the

Santa Clara County Health Authority Pharmacy & Therapeutics Committee

Thursday, June 17, 2021, 6:00 PM – 8:00 PM

Santa Clara Family Health Plan

6201 San Ignacio Ave, San Jose, CA 95119

Minutes (Closed) - Draft

Members Present

Jimmy Lin, MD, Chair
Ali Alkoraishi, MD
Dang Huynh, PharmD, Director of Pharmacy and UM
Laurie Nakahira, DO, Chief Medical Officer
Jesse Parashar-Rokicki, MD

Members Absent

Xuan Cung, PharmD
Dolly Goel, MD
Peter Nguyen, DO

Staff Present

Duyen Nguyen, PharmD, Clinical Pharmacist
Tami Otomo, PharmD, Clinical Pharmacist
Kelly Davey, Supervisor, Grievance & Appeals
Kathy Le, PharmD, Pharmacy Resident
Nancy Aguirre, Administrative Assistant

Others Present

Amy McCarty, PharmD, MedImpact

1. Roll Call

Jimmy Lin, MD, Chair, called the meeting to order at 6:05 pm. Roll call was taken and a quorum was established.

2. Public Comment

There were no public comments.

3. Open Meeting Minutes

The 1Q2021 P&T Committee open meeting minutes were reviewed.

It was moved, seconded and the open minutes of the 1Q2021 P&T meeting minutes were **unanimously approved.**

Motion: Dr. Parashar-Rokicki

Second: Dr. Alkoraishi

Ayes: Dr. Huynh, Dr. Lin, Dr. Nakahira

Absent: Dr. Cung, Dr. Goel, Dr. Nguyen

4. Standing Agenda Items

a. Chief Medical Officer Health Plan Updates

Laurie Nakahira, DO, Chief Medical Officer (CMO), presented the CMO Health Plan Updates. Dr. Nakahira reported the current plan membership was approximately 282,670 total members, reflecting an 11.3% increase over the last year, since June 2020. Of the total membership, approximately 10,080 were Cal MediConnect (CMC) members and 272,590 were Medi-Cal (MC) members.

Dr. Nakahira noted that the public health shelter-in-place order was lifted on June 15, and there were also changes to face mask requirements.

The plan will take the 2021/2022 budget and organizational goals to the board meeting at the end of the month for approval.

The plan is working on NCQA reaccreditation for CMC, Medi-Cal NCQA agreements with delegates, and NCQA distinction for multicultural healthcare. For CalAIM, SCFHP plans to implement enhanced care management in January 2022. The plan is also creating a population health management strategy to align with CalAIM.

Upcoming projects include behavioral health prevention in schools and increased access to behavioral health.

SCFHP continues to work on the return to office/work from home plan. Dr. Nakahira stated that it was not clear when committee meetings will resume in person.

Dr. Nakahira noted that there have been immunization events held at SCFHP's Community Resource Center (CRC). However, the CRC has not yet opened for business.

b. Medi-Cal Rx Update

Dang Huynh, PharmD, Director, Pharmacy and Utilization Management presented the Medi-Cal Rx Update. Plans were supposed to get an update in mid-May, but no updates were received. Dr. Huynh stated that he will report any new developments.

c. Grievance & Appeals Report – 1Q 2021

Kelly Davey, Supervisor, Grievance & Appeals (G&A), presented the G&A Report for 1Q2021.

For MC, there was an increase in appeals volume from month to month; March appeals volume was almost double that of January. Ciclopirox, clobetasol, and Restasis were the top drugs appealed. The percentage of cases upheld were similar for each month.

For CMC, there was a similar trend where appeals volume increased from month to month. A few of the common drugs appealed were Eplclusa and lidocaine.

d. Plan/Global Medi-Cal Drug Use Review

i. Drug Utilization Evaluation Update

Tami Otomo, PharmD, Clinical Pharmacist, shared the results from SCFHP's quarterly retrospective Drug Use Evaluation (DUE) program. For Q2 2021, MC and CMC had different topics.

For MC, the focus was congestive heart failure, where the program identified members with heart failure who may benefit from an ACE-I or ARB, which combined with certain beta-blockers, reduce death and morbidity in these patients. There were 185 impacted members, and 126 providers were mailed letters on May 19, 2021.

For CMC, the focus was polypharmacy, where the program identified members taking more than 10 unique chronic meds from three or more prescribers in a three month period and would benefit from a review of their prescriptions and simplified drug therapy, if appropriate. There were 511 impacted members, and 245 providers were mailed letters on May 21, 2021.

ii. DHCS DUR Annual Survey

The plan submitted the DHCS DUR Annual Survey timely and included the completed survey in the committee's packet.

e. Emergency Supply Report – 2Q 2020

Duyen Nguyen, PharmD, Clinical Pharmacist, presented the Emergency Supply Report for 2Q 2020. There were no issues with approved or denied claims. Out of the members with no claims, one member had a denied claim for cefpodoxime 11 days after the emergency room admission date. This member did not have approved claims for any antibiotics. The plan identified this as an opportunity to inform pharmacies of the covered alternative for cefpodoxime and subsequently implemented a point-of-sale message stating that the formulary alternative is cefdinir.

Adjourned to Closed Session at 6:27p.m.

Pursuant to Welfare and Institutions Code Section 14087.36 (w)

5. Closed Meeting Minutes

The 1Q2021 P&T Committee closed meeting minutes were reviewed.

It was moved, seconded and the closed minutes of the 1Q2021 P&T meeting minutes were **unanimously approved**.

Motion: Dr. Parashar-Rokicki

Second: Dr. Huynh

Ayes: Dr. Alkoraishi, Dr. Lin, Dr. Nakahira

Absent: Dr. Cung, Dr. Goel, Dr. Nguyen

6. Metrics and Financial Updates

a. Membership Report

The Membership Report was presented by Dr. Nakahira during the CMO Update.

b. Pharmacy Dashboard

Dr. Otomo reviewed the Pharmacy Dashboard for January to May 2021.

c. Drug Utilization & Spend – 1Q 2021

Amy McCarty, PharmD, MedImpact, presented the Drug Utilization and Spend for 1Q2021.

7. Discussion and Recommendations for Changes to SCFHP's Medical Benefit Drug Prior Authorization Grid

a. Medical Benefit Drug PA Grid Modifications

Dr. Otomo shared updates to the Medical Benefit Drug PA Grid.

It was moved, seconded and the Medical Benefit Drug PA Grid Modifications were **unanimously approved**.

Motion: Dr. Huynh

Second: Dr. Alkoraishi

Ayes: Dr. Lin, Dr. Nakahira, Dr. Parashar-Rokicki,

Absent: Dr. Cung, Dr. Goel, Dr. Nguyen

8. Discussion and Recommendations for Changes to SCFHP's Cal MediConnect Formulary & Coverage Determination Criteria

a. Pharmacy Benefit Manager 1Q 2021 P&T Minutes

Dr. McCarty referenced the Pharmacy Benefit Manager 1Q 2021 P&T Minutes included in the meeting packet.

b. Pharmacy Benefit Manager 2Q2021 P&T Part D Actions

Dr. McCarty reviewed the Pharmacy Benefit Manager 2Q 2021 P&T Part D Actions.

It was moved, seconded and the Pharmacy Benefit Manager 1Q 2021 P&T Minutes and 2Q2021 P&T Part D Actions were **unanimously approved**.

Motion: Dr. Huynh

Second: Dr. Lin

Ayes: Dr. Alkoraishi, Dr. Nakahira, Dr. Parashar-Rokicki,

Absent: Dr. Cung, Dr. Goel, Dr. Nguyen

9. Discussion and Recommendations for Changes to SCFHP's Medi-Cal Formulary & Prior Authorization Criteria

a. Old Business/Follow-Up

Dr. Lin noted there were no updates to report.

b. Formulary Modifications

Dr. Otomo presented the changes made to the Medi-Cal formulary since the last P&T Committee meeting in March 2021.

It was moved, seconded and the Formulary Modification were **unanimously approved**.

Motion: Dr. Alkoraishi

Second: Dr. Lin

Ayes: Dr. Huynh, Dr. Nakahira, Dr. Parashar-Rokicki,

Absent: Dr. Cung, Dr. Goel, Dr. Nguyen

c. Fee-for-Service Contract Drug List Comparability

Dr. McCarty reviewed the Fee-for-Service (FFS) Contract Drug List (CDL) Comparability for MC.

d. Prior Authorization Criteria

Dr. Nguyen reviewed the Prior Authorization Criteria.

iii. New or Revised Criteria

1. Tadalafil (Adcirca)
2. Dimethyl Fumarate (Tecfidera)
3. Amitiza (lubiprostone)
4. Brand Name
5. Copaxone (glatiramer acetate)
6. Gilenya (fingolimod)
7. Humira (adalimumab)

iv. Annual Review

1. Androgel (testosterone gel)
2. Ciprodex (ciprofloxacin/dexamethasone)
3. Diabetic Supplies
4. Dovonex (calcipotriene)
5. Elmiron (pentosan polysulfate)
6. Exelon (rivastigmine)
7. Hycet (hydrocodone/acetaminophen sol)
8. Intron A (interferon alfa-2b)
9. Lovaza (omega-3 acid ethyl esters)
10. Lysteda (tranexamic acid)
11. Makena (hydroxyprogesterone caproate)

12. Malarone (atovaquone/proguanil)
13. Marinol (dronabinol)
14. Mavyret (glecaprevir/pibrentasvir)
15. Mycobutin (rifabutin)
16. Nebupent (pentamidine)
17. Oral liquids - Non-formulary
18. Pain Medication - Terminally ill
19. Provigil (modafinil)
20. Reauthorization
21. Restatis, Cequa (cyclosporine)
22. Revatio (sildenafil)
23. Santyl (collagenase)
24. Sporanox (itraconazole)
25. Symlin (pramlintide)
26. Tymlos (abaloparatide)
27. Viroptic (trifluridine)
28. Xenazine (tetrabenazine)
29. Hepatitis C
30. Rhopressa (netarsudil)
31. Oncology
32. Epclusa (sofobuvir/velpatasvir)

It was moved, seconded and the Prior Authorization Criteria was unanimously approved.

Motion: Dr. Huynh

Second: Dr. Lin

Ayes: Dr. Alkoraishi, Dr. Nakahira, Dr. Parashar-Rokicki

Absent: Dr. Cung, Dr. Goel, Dr. Nguyen

10. New Drugs and Class Reviews

a. S1P Receptor Modulators – Multiple Sclerosis

Kathy Le, PharmD, Pharmacy Resident reviewed the background, place in therapy, clinical efficacy, safety, and cost & utilization data of S1P receptor modulators for multiple sclerosis.

b. Pulmonary Arterial Hypertension

Dr. McCarty presented an overview of pulmonary arterial hypertension, the available treatment options, and cost and utilization data.

c. Oral Azole Antifungals

Dr. McCarty presented an overview of oral azole antifungals, their approved indications, place in therapy per IDSA treatment guidelines, dosing and cost information, and 1Q2021 utilization.

d. Actinic Keratosis

Dr. McCarty presented an overview of actinic keratosis, the available treatment options, and cost and utilization data.

e. Farxiga – Chronic Kidney Disease

Dr. McCarty presented an overview of Farxiga used for chronic kidney disease.

f. New Entities – Tepmetko, Qelbree

Dr. McCarty presented an overview of two new entities: Tepmetko and Qelbree.

g. New Formulations – Vesicare LS, Bronchitol, Elepsia XR, Roszet

Dr. McCarty presented an overview of the following new drug formulations: Vesicare LS, Bronchitol, Elepsia XR, and Roszet.

h. New Indications – Gocovri, Actemra, Praluent

Dr. McCarty presented an overview of the new indications for Gocovri, Actemra, and Praluent.

i. New & Expanded Indications – *Informational Only*

It was moved, seconded and the recommendations for New Drugs and Class Reviews were **unanimously approved.**

Motion: Dr. Huynh

Second: Dr. Lin

Ayes: Dr. Alkoraishi, Dr. Nakahira, Dr. Parashar-Rokicki

Absent: Dr. Cung, Dr. Goel, Dr. Nguyen

Reconvene in Open Session at 7:58 p.m.

11. Discussion Items

a. New and Generic Pipeline

Dr. McCarty reviewed the New and Generic Pipeline. Generic Gilenya and generic Forteo may be released in 4Q21.

12. Adjournment

The meeting adjourned at 8:01 p.m. The next P&T Committee meeting will be on Thursday, September 16, 2021.

Jimmy Lin, MD, Chair

Date

Pharmacy & Therapeutics Committee

STANDING AGENDA ITEMS

Drug Utilization Evaluation (DUE) Outcomes



Copyright © 2020 MedImpact Healthcare Systems, Inc. All rights reserved.

The contents of this presentation are confidential and proprietary to MedImpact Healthcare Systems, Inc. and may contain material MedImpact considers Trade Secrets. This presentation may not be reproduced, transmitted, published, or disclosed to others without MedImpact's prior written authorization.

Asthma DUE

Asthma: Identify members receiving four or more prescriptions for an asthma medication over a 12-month period (persistent asthma), who are not on a controller medication (e.g., inhaled steroid, leukotriene antagonist, Xolair, etc.).



MediCal =

- 731 members identified (7/1/2019 to 6/30/2020)
- 339 prescriber letters sent
- 703 members still active in follow up period (7/1/2020 to 6/30/2021)
- 467 members no longer identified in follow up period
- **Asthma DUE = 66% success rate**



Cal MediConnect =

- 74 members identified (7/1/2019 to 6/30/2020)
- 63 prescriber letters sent
- 70 members still active in follow up period (7/1/2020 to 6/30/2021)
- 37 members no longer identified in follow up period
- **Asthma DUE = 53% success rate**

Pharmacy & Therapeutics Committee

DISCUSSION ITEMS

High impact/interest pipeline.

2nd Quarter 2021

Aduhelm (Alzheimer's)-BT †
 Lumakras (lung cancer) -BT
 Myfembree (fibroids)-C
 Nurtec ODT (migraine prevention) -NI
 Trikafta (cystic fibrosis) -NI
 sotrovimab (Covid-19)- C
 Actemra (Covid-19)- NI

4th Quarter 2021

avacopan (ANCA vasculitis) -BT
 bimekizumab (plaque psoriasis) -C
 Cilta-cel (multiple myeloma)-BT †
 efgartigimod (myasthenia gravis)-BT †
 Verzenio (breast cancer) -NI
 vosoritide (achondroplasia) -BT

NOT YET FILED

cabotegravir (HIV PrEP) -BT †

2Q21

3Q21

4Q21

1Q22

2Q22



3rd Quarter 2021

abrocitinib, Olumiant & Rinvoq (atopic dermatitis) -C
 asciminib (chronic myelogenous leukemia) -C
 atogepant (migraine prevention) -C
 Bylvay (PFIC) -BT
 Korsuva (pruritus with HD) -BT
 maralixibat (Alagille syndrome)-BT
 Rolontis (neutropenia)-C
 roxadustat (anemia of CKD)-C
 teplizumab (delay of diabetes type 1) -BT

1st Quarter 2022

inclisiran (hypercholesterolemia)-C
 mavacamten (obstructive cardiomyopathy) -BT
 tezepelumab (severe asthma) -BT

KEY

C = Agent will **compete** with current standard of care

A = Agent will be used in **addition** to current therapy or expands the patient population treated

BT = Agent is a **breakthrough**/novel treatment in an area where no comparable drug therapy previously existed

NI = Previously approved agent with a **new indication** (high impact)

† = Medical Cost

* = Complete Response Letter

= Emergency Use Authorization



Generic pipeline.

High impact

Sept 2021

Bystolic

2H2021

Chantix

Restasis*

March 2022

Revlimid

Vimpat

3Q2021

4Q2021

1Q2022

July 2021

Feraheme

2H2021

Jevtana Kit

Aug 2021

Sutent*

Nov 2021

Gilenya 0.25mg

2021

Forteo

Durezol

Afinitor 10mg*

Byetta*

Daliresp

Epiduo Forte

Toviaz

Jan 2022

Oxaydo

Feb 2022

Selzentry 150mg,
300mg

Medium/Low impact

Bold font = new to slide

Red font = launched

*NO exclusivity

† Authorized Generic

